Switzerland (CH)

Tandem-L: Main Results of the Phase A Feasibility Study (2016) Krieger G, Moreira A, Zink M, Hajnsek I, Huber S, Villano M, Papathanassiou K, et al. Conference contribution COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA (2016) Kratz A, Sahm F, Schrimpf D, Jones DT, Reuss D, Koelsche C, Huang K, et al. Conference contribution Additive fabrication of nanostructures with focused soft X-rays (2016) Späth A, TU F, Vollnhals F, Drost M, Krick Calderon S, Watts B, Fink R, Marbach H Journal article Risk factors for mental disorders develop early in German students of dentistry (2016) Scholz M, Neumann C, Ropohl A, Paulsen F, Burger PHM Journal article Integration of the musculature in the course "functional anatomy of the locomotor system"-Preparing medical students for the dissection course (2016) Hammer C, Paulsen F, Burger PHM, Scholz M Journal article Development of depression and deterioration in quality of life in German dental medical students in preclinical semesters (2016) Burger PHM, Neumann C, Ropohl A, Paulsen F, Scholz M Journal article Type 2 Innate Lymphoid Cells - Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis (2016) Weber S, Wohlfahrt T, Rauber S, Luber M, Englbrecht M, Dees C, Beyer C, et al. Conference contribution Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial (2016) Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution THE INVOLVEMENT OF THE LONG NONCODING H19X IN TGF beta SIGNALING AND ITS PROFIBROTIC EFFECTS IN SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES (2016) Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Dobrota R, Brock M, Kurreeman F, et al. Conference contribution SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1 (2016) Kavanaugh A, Mease P, Reimold A, Tahir H, Rech J, Hall S, Geusens P, et al. Conference contribution